Literature DB >> 28153508

Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.

Uma Krishnamurti1, Ceyda Sonmez Wetherilt2, Jing Yang3, Limin Peng4, Xiaoxian Li5.   

Abstract

Correlation between tumor-infiltrating lymphocytes (TILs) and complete pathological response (pCR) in breast cancers in neoadjuvant settings have been reported. In this study, we analyzed the association between TILs and diagnostic and prognostic parameters in estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC) without neoadjuvant treatments. Three hundred forty-four (344) patients who underwent mastectomy for breast cancer (187 ER+ and 157 TNBC) without neoadjuvant treatments were evaluated. Percentage of overall and peripheral TILs were correlated with lymphovascular invasion (LVI), Nottingham histologic grade (NHG, 1/2 versus 3), stage, lymph node status (LN), overall survival (OS), and disease-free survival (DFS). In TNBC, both peripheral and overall TILs were significantly associated with NHG 3 (P<.0001). Peripheral but not overall TILs were significantly associated with better OS (hazard ratio [HR]: 0.95; 95% confidence interval [CI]: 0.91-1.00; P=.0354) and DFS (HR: 0.95; 95% CI: 0.91-1.00; P=.0314) in univariate and multivariate analysis. In ER+ breast cancer, only peripheral TILs were associated with NHG 3 (P=.018) but not with OS or DFS (both P>.05). In ER+ breast cancer, there was a negative association between Oncotype DX recurrence score and both overall (P=.0007) and peripheral TILs (P=.0119). In conclusion, peripheral but not overall TILs correlate with better OS and DFS in TNBC, indicating the location of TILs may be important in TNBC. The negative association between TILs and Oncotype DX score in ER+ may indicate the possible prognostic value of TILs in ER+ breast cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant therapy; Breast carcinoma; Disease-free survival; Non-neoadjuvant therapy; Overall survival; TIL; Tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 28153508     DOI: 10.1016/j.humpath.2017.01.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  25 in total

1.  Single Cell Genomics for Tumor Heterogeneity.

Authors:  Hae-Ock Lee; Woong-Yang Park
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.

Authors:  Marco Galvez; Carlos A Castaneda; Joselyn Sanchez; Miluska Castillo; Lia Pamela Rebaza; Gabriela Calderon; Miguel De La Cruz; Jose Manuel Cotrina; Julio Abugattas; Jorge Dunstan; Henry Guerra; Omar Mejia; Henry L Gomez
Journal:  World J Clin Oncol       Date:  2018-04-10

3.  Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.

Authors:  Jane Meisel; Chao Zhang; Cameron Neely; Pia Mendoza; Shuo You; Tatiana Han; Yuan Liu; Aysegul A Sahin; Ruth O'Regan; Xiaoxian Li
Journal:  Clin Breast Cancer       Date:  2017-12-14       Impact factor: 3.225

Review 4.  Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.

Authors:  Nicolas A Giraldo; J David Peske; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Virchows Arch       Date:  2019-01-10       Impact factor: 4.064

5.  The scope of viral causation of human cancers: interpreting virus density from an evolutionary perspective.

Authors:  Paul W Ewald; Holly A Swain Ewald
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

6.  Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.

Authors:  Thi Truc Anh Nguyen; Lauren M Postlewait; Chao Zhang; Jane L Meisel; Ruth O'Regan; Sunil Badve; Kevin Kalinsky; Xiaoxian Li
Journal:  Breast Cancer Res Treat       Date:  2022-01-27       Impact factor: 4.872

Review 7.  Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers.

Authors:  Peter Savas; Roberto Salgado; Sherene Loi
Journal:  Breast Cancer Res Treat       Date:  2021-09-06       Impact factor: 4.872

8.  Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score.

Authors:  Hongxiao Li; Jigang Wang; Zaibo Li; Melad Dababneh; Fusheng Wang; Peng Zhao; Geoffrey H Smith; George Teodoro; Meijie Li; Jun Kong; Xiaoxian Li
Journal:  Front Med (Lausanne)       Date:  2022-06-14

9.  First international TNBC conference meeting report.

Authors:  Padmashree Rida; Angela Ogden; Ian O Ellis; Zsuzsanna Varga; Antonio C Wolff; Tiffany A Traina; Christos Hatzis; Julie R Palmer; Christine B Ambrosone; Brian D Lehmann; Rita Nanda; Valerie Montgomery Rice; Otis W Brawley; Mylin A Torres; Emad Rakha; Ritu Aneja
Journal:  Breast Cancer Res Treat       Date:  2018-02-08       Impact factor: 4.872

10.  Relationship of the standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm.

Authors:  Soeun Park; Eun-Ki Min; Soong June Bae; Chihwan Cha; Dooreh Kim; Janghee Lee; Yoon Jin Cha; Sung Gwe Ahn; Joon Jeong
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.